Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 18/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17602096 | 0.81 | KDM4C (0.67) | KDM4C | |
| SCHEMBL22163336 | 0.81 | KDM4C (0.50) | KDM4C | |
| SCHEMBL19268161 | 0.76 | LATS1 (0.42) | KDM4C | |
| SCHEMBL19268160 | 0.75 | KDM4C (0.42) | KDM4C | |
| SCHEMBL19268159 | 0.75 | KDM4C (0.43) | KDM4C | |
| SCHEMBL22163584 | 0.74 | KDM4C (0.59) | KDM4C | |
| SCHEMBL19268157 | 0.74 | KDM4C (0.42) | KDM4CHRH3 | |
| SCHEMBL17602060 | 0.74 | KDM4C (0.69) | KDM4C | |
| SCHEMBL17898316 | 0.72 | KDM4C (0.55) | KDM4C | |
| SCHEMBL17615773 | 0.72 | KDM4C (0.53) | KDM4CTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202381-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202381-B2 | Histone demethylase inhibitors | KDM1B, KDM5C, KDM1A | KDM4C 9/4885TRPV1 4154/4885HRH3 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.